Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06350097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06350097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
April 29, 2024
Completion date
August 29, 2031
Enrollment
582 (estimated)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer